Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY, a HUMIRA® biosimilar, available to patients
YUSIMRY (adalimumab-aqvh) will be the first biologic product offered by the Mark Cuban Cost Plus Drug Company YUSIMRY will be […]